Nuveen’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-275,753
| Closed | -$1.47M | – | 3653 |
|
|
2021
Q1 | $1.47M | Sell |
275,753
-137,229
| -33% | -$3.42M | ﹤0.01% | 2749 |
|
|
2020
Q4 | $2.21M | Buy |
412,982
+249,136
| +152% | +$3.12M | ﹤0.01% | 2461 |
|
|
2020
Q3 | $770K | Buy |
163,846
+30,409
| +23% | +$154K | ﹤0.01% | 2798 |
|
|
2020
Q2 | $814K | Sell |
133,437
-25,368
| -16% | -$104K | ﹤0.01% | 2705 |
|
|
2020
Q1 | $361K | Buy |
158,805
+49,117
| +45% | +$208K | ﹤0.01% | 2882 |
|
|
2019
Q4 | $503K | Sell |
109,688
-505,259
| -82% | -$2M | ﹤0.01% | 2906 |
|
|
2019
Q3 | $2.38M | Buy |
614,947
+96,187
| +19% | +$528K | ﹤0.01% | 2324 |
|
|
2019
Q2 | $3.13M | Buy |
+518,760
| New | +$4.96M | ﹤0.01% | 2226 |
|
|
2017
Q1 | – | Sell |
-16,175
| Closed | -$811K | – | 1518 |
|
|
2016
Q4 | $811K | Sell |
16,175
-97
| -0.6% | -$5.1K | ﹤0.01% | 1219 |
|
|
2016
Q3 | $854K | Buy |
16,272
+200
| +1% | +$9.55K | 0.01% | 1127 |
|
|
2016
Q2 | $665K | Buy |
16,072
+1,267
| +9% | +$55.1K | ﹤0.01% | 1129 |
|
|
2016
Q1 | $602 | Buy |
+14,805
| New | +$509K | ﹤0.01% | 1180 |
|
Nuveen's FPRX Position: Q2 2021 in Review
Nuveen sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 275,753 shares — an estimated $1.47M sold.
Nuveen first reported a position in FPRX in Q1 2016 and held it in 12 quarters. The position peaked at $3.13M in Q2 2019. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Nuveen reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Nuveen sold 275,753 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.47M.
- Nuveen first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 12 quarters.
- Nuveen's Five Prime Therapeutics, Inc. position peaked at $3.13M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.